Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports a rare side effect of trichiasis in a patient with spinal chordoma treated with Afatinib, a type of epidermal growth factor receptor tyrosine kinase inhibitor.

In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.

This article discusses emerging therapies for androgenetic alopecia, highlighting the use of intradermal dutasteride, but it reports no new clinical findings.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

In this study, once-daily treatment with bimatoprost 0.03% solution significantly increased eyelash growth, thickness, and darkness in patients with chemotherapy-induced eyelash loss compared to placebo, and was well tolerated over one year.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

This study demonstrated that topical anthralin at concentrations of 0.1% to 1% is effective and well-tolerated for treating pediatric alopecia areata, with 0.2% offering the best results and requiring at least six months of treatment to achieve substantial hair regrowth.

In this study, tazarotene 0.1% gel showed greater efficacy than tretinoin 0.025% gel in reducing acne lesions and demonstrated similar efficacy to adapalene 0.1% gel when used less frequently.

This study found that combined therapy with cetirizine and topical steroids stabilized inflammation in most patients with lichen planus pilaris, though one patient experienced cardiac arrhythmia.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This review discusses the challenges in diagnosing and managing asthma in older adults and reports no new results; the authors emphasize the importance of addressing comorbidities and potential medication adverse events.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This review concluded that while topical prostaglandin analogues show some potential in treating androgenetic alopecia, evidence is still limited and no products have regulatory approval.

In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.

This article addresses an unusual side effect of azathioprine but provides no abstract or detailed results, focusing instead on a specific dermatological perspective.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

CTP-543 is generally safe for treating alopecia areata.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

This study observed that early treatment with ritlecitinib in patients with alopecia areata, especially when severity is low, led to more favorable responses, and continued improvement was seen up to 24 months, offering guidance on treatment timing and duration.

In this study, EFH-SLM cream demonstrated greater efficiency in reducing hair density compared to plain EFH cream in Swiss albino female mice, with significantly less skin irritation and inflammation observed, suggesting improved permeability and effectiveness of EFH when using the new cream formulation.